Takeda and Zinfandel write off yet another Alzheimer’s PhIII after Actos fails a key interim test
Hours after Eli Lilly spelled out exactly how bad its last batch of Phase III data for solanezumab was, Takeda stepped up to say its big shot at proving that their diabetes drug Actos could also delay symptoms of Alzheimer’s was a complete flop.
Described as the biggest Phase III in Alzheimer’s to date when it was fully enrolled in early 2016, the TOMORROW study recruited more than 3,500 patients at 50 sites to test a low dose of Actos, using a genetic-based biomarker risk assignment algorithm from the small US biotech Zinfandel Pharmaceuticals, a Duke spinout, to identify the best subjects.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.